Latest Psychedelic Therapy News

Emyria has inked a pivotal agreement with Avive Health to launch its first Empax clinic in Queensland, expanding its innovative mental health treatment network. This move builds on its recent Medibank partnership, advancing accessible, reimbursed care for treatment-resistant conditions.

Emyria has secured a landmark multi-year funding agreement with Medibank to reimburse PTSD patients under its Empax program, alongside opening a second clinic and reporting durable clinical improvements in treatment-resistant PTSD cases.

Vitura Health’s joint venture Flora Holdings has acquired Heyday Medical Clinic, a leading medicinal cannabis provider, enhancing its national clinical network and patient access across Australia.

Emyria reports sustained and statistically significant improvements in PTSD symptoms and quality of life three months after MDMA-assisted therapy, signaling a potential breakthrough for treatment-resistant patients.

Tryptamine Therapeutics has reported successful Phase 1b results for its IV-infused psilocin candidate TRP-8803 and promising interim data for oral psilocybin TRP-8802 in IBS treatment, while securing $6 million in new funding to accelerate clinical development.

Emyria Limited announces key leadership shifts with Greg Hutchinson stepping up as Executive Chairman and Dr. Michael Winlo transitioning to Chief Scientific Officer, aiming to scale innovative mental health therapies amid growing demand.